harmacogenetic research has the potential to improve drug response; however, variation is diverse across populations. [1] [2] [3] [4] Information about the prevalence of pharmacogenetic variation among AI/AN people is largely lacking and limited data suggest that variation in American indigenous people is highly variable. [5] [6] [7] We have reported the first comprehensive evaluation of pharmacogenetic variation
Genetic research represents an area of special concern for many AI/AN communities 6, 7, [14] [15] [16] [17] [18] [19] [20] [21] ; many of the issues are welldescribed in the AI/AN Genetics Resource Center, developed by the National Congress of American Indians. 22 Important barriers to genetic research include concerns about privacy, misuse of DNA specimens, and fear of stigmatizing interpretations of genetic information. 6, 7, 17, [19] [20] [21] In some communities, fear exists that genetic information could be used without tribal permission to oppose culturally established definitions of relatedness and family membership, qualifications for tribal enrollment, or challenge the validity of treaty rights. 15, 16, 18, 21 To overcome these concerns, AI/AN communities have advocated for a CBPR model to transform research practices in their communities. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] A CBPR approach engages both researchers and communities in a partnership to define research questions to improve the health of AI/AN people and allows partners to work together to build trustworthy research practices and reduce the risk of abuse. Different models of CBPR have been proposed, but all have at their center a commitment to shared power and a turn away from community members as "subjects" of research to participants in the research process.
As part of the Northwest-Alaska Pharmacogenomics Research
Network (NWA-PGRN), we have used a CBPR approach to conduct pharmacogenetic research with AI/AN populations. 6, 7 NWA-PGRN research was initiated by university-based researchers who identified a research opportunity they thought might be of interest to tribal groups and approached three tribal organizations in Montana and Alaska about the possibility of pursuing pharmacogenetic research together and defining the area of greatest interest at each site. 6, 7 In this report, we reflect on the growth of a pharmacogenetic partnership with the UM and the CSKT of the Developing an Academic-Community Partnership: Evaluating Our Progress
As part of our shared commitment to building a sustainable, trust-based partnership, we undertook a mixed-methods approach to assessing our progress. These activities were not undertaken as human subjects research, but rather as a selfevaluation of our partnership; thus, no institutional review (Table 2) and was distributed at a CPAC meeting (June 2013).
For the qualitative portion of the self-assessment, interview questions were developed by C.T.M., S.B.T., R.J., and E.L.W.
( Table 3 I had never really thought about drugs, how they act, and how they react, and how they do what they're supposed to do. And how that might vary from person to person or from group to group because of the gene pool in that group. I had never really thought about that. I got the basic understanding of how the chemistry is supposed to work in treating cancer and how the chemotherapy is supposed to work and how that might be affected by the genes of the person and how to test and control for that to see if the different genes really do have an effect on the effectiveness of the drugs.
In addition, a member said, "being a part of this group has really actually made me want to learn how genetics works, There are cultural traditions related to elders and . . . letting them speak first. Which I knew something about, but seeing that in action in the community is different. Maybe doing a little more listening and a little less talking than you see a lot in non-Indian cultures . . . Maybe learning to listen a little more. Concepts of time are a bit different . . . [We] think that this is the most important thing in the world but maybe somebody else doesn't.
Tribally affiliated researchers shared that, although their Native background provided them with cultural familiarity, conducting community-based work provided advantages.
One reflected that:
As a tribal member, although not from the CSKT community, there is some cultural knowledge that I have that has prepared me and translated over in working with the CPAC. And at the same time, there is a lot of knowledge that I don't know and have learned and is even more important that I continue to listen and be patient through the partnership.
Another In addition, the CPAC mentioned their support for younger generations to become involved and to participate in research.
Researchers were asked how the partnership has impacted their work. One researcher commented on the cultural knowledge she has learned from CPAC members:
You adjust your thinking and you adjust your approach. You come from a society where everything is go go go, fast fast fast, get the answer. If you don't come up with the answer very quickly in our society, people think you're not as smart as somebody else . . . I notice [now] when someone is not speaking up and I will wait for them.
Another researcher described how this partnership provided her with cultural knowledge and prompted her involvement in other CBPR projects outside of NWA-PGRN:
Some of the early experiences I had on the pharmacogenomics project have helped in creating new projects related to cancer and community engagement. For example, we created . . . brochures to work with clinicians using a culturally appropriate approach. And these are all working with Native groups . . . So for all of these projects, some of the background I received from the pharmacogenomics exposure were really helpful in terms of understanding the cultural pieces better.
One researcher discussed how "family is important, lin- 
